US EditionImmune Checkpoint Inhibitors Linked to Elevated Myocarditis Risk in NSCLC
Summary by Scienmag: Latest Science and Health News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Immune Checkpoint Inhibitors Linked to Elevated Myocarditis Risk in NSCLC
A groundbreaking editorial recently published in the latest volume of Oncoscience sheds new light on the complex relationship between immune checkpoint inhibitors (ICIs) and myocarditis, an immune-mediated inflammation of the heart muscle. As ICIs become a mainstay in the treatment of advanced non-small cell lung cancer (NSCLC), understanding their rare but serious adverse effects is paramount for optimizing patient safety and treatment outcomes…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
